Omnicell (OMCL) Hisse Özeti
Omnicell, Inc. iştirakleri ile birlikte Amerika Birleşik Devletleri'nde ve uluslararası alanda sağlık teknolojisi sağlamaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 1/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden OMCL için herhangi bir risk tespit edilmedi.
OMCL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Omnicell, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$45.59 |
| 52 Haftanın En Yüksek Seviyesi | US$55.00 |
| 52 Haftanın En Düşük Seviyesi | US$26.85 |
| Beta | 0.97 |
| 1 Aylık Değişim | 12.04% |
| 3 Aylık Değişim | 32.53% |
| 1 Yıllık Değişim | 53.14% |
| 3 Yıllık Değişim | -37.87% |
| 5 Yıllık Değişim | -69.79% |
| Halka arzdan bu yana değişim | 379.39% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 06
OMCL: Cabinet Replacement Cycle Will Support Higher Multiple As New Leadership Executes
Omnicell's updated analyst price target has increased from $63 to $70. Analysts cited adjusted fair value, refined discount rate assumptions, and expectations for a higher future P/E multiple to support the change.
Anlatı Güncellemesi • Jun 22
OMCL: Earnings Rebound And Guidance Will Support Higher Future Earnings Multiple
Analysts have nudged their price targets on Omnicell higher, with recent Street research pointing to modestly improved expectations that support a slightly richer long term fair value framework anchored around $55. Analyst Commentary Recent Street research on Omnicell reflects a mixed tone, with higher price targets framed within a cautious backdrop.Analiz Makalesi • Jun 21
Omnicell (OMCL) Stock Could Be 36.3% Undervalued After Specialty Pharmacy Leadership Hire
Omnicell (OMCL) stock is back in focus after the company appointed veteran pharmacy operator Dan Mandoli as Senior Vice President and General Manager of Specialty Pharmacy Services, a move tied directly to its Specialty Pharmacy and 340B ambitions. See our latest analysis for Omnicell. Omnicell’s latest leadership change comes after a mixed stretch in the market, with the stock’s share price showing a 13.82% 90 day return but down 12.07% over 30 days, while the 1 year total shareholder return...Recent updates
Anlatı Güncellemesi • Jul 06
OMCL: Cabinet Replacement Cycle Will Support Higher Multiple As New Leadership Executes
Omnicell's updated analyst price target has increased from $63 to $70. Analysts cited adjusted fair value, refined discount rate assumptions, and expectations for a higher future P/E multiple to support the change.Anlatı Güncellemesi • Jun 22
OMCL: Earnings Rebound And Guidance Will Support Higher Future Earnings Multiple
Analysts have nudged their price targets on Omnicell higher, with recent Street research pointing to modestly improved expectations that support a slightly richer long term fair value framework anchored around $55. Analyst Commentary Recent Street research on Omnicell reflects a mixed tone, with higher price targets framed within a cautious backdrop.Analiz Makalesi • Jun 21
Omnicell (OMCL) Stock Could Be 36.3% Undervalued After Specialty Pharmacy Leadership Hire
Omnicell (OMCL) stock is back in focus after the company appointed veteran pharmacy operator Dan Mandoli as Senior Vice President and General Manager of Specialty Pharmacy Services, a move tied directly to its Specialty Pharmacy and 340B ambitions. See our latest analysis for Omnicell. Omnicell’s latest leadership change comes after a mixed stretch in the market, with the stock’s share price showing a 13.82% 90 day return but down 12.07% over 30 days, while the 1 year total shareholder return...
Anlatı Güncellemesi • Jun 04
OMCL: Cabinet Replacement Cycle Will Support Stronger Future Medication Management Demand
Analysts have lifted their price target on Omnicell by $12 in total, supported by refreshed assumptions on discount rate, revenue growth, profit margin and future P/E. These changes leave the stock's fair value estimate broadly unchanged at about $61.29.Anlatı Güncellemesi • May 19
OMCL: Cabinet Replacement Cycle Will Support Stronger Future Medication Management Upside
Analysts lifted the Omnicell price target by about $4, reflecting updated fair value estimates and revised assumptions on discount rate, revenue growth, profit margin, and future P/E multiples, supported by recent research from multiple firms. Analyst Commentary Recent Street research includes price target increases of about $2 and $10, which gives a sense of how bullish and cautious views are being weighed around Omnicell right now.Analiz Makalesi • May 14
Omnicell's (NASDAQ:OMCL) Conservative Accounting Might Explain Soft Earnings
The market was pleased with the recent earnings report from Omnicell, Inc. ( NASDAQ:OMCL ), despite the profit numbers...Anlatı Güncellemesi • May 01
OMCL: New Product Cycle Will Reset Expectations And Support Higher Future Earnings Multiple
Analysts have reset their view on Omnicell, with the consolidated fair value estimate moving from $49.00 to $55.00. This reflects updated assumptions on discount rate, growth, margins and future P/E, alongside recent price target hikes and rating changes across the Street.Anlatı Güncellemesi • Apr 16
OMCL: New Product Cycle Will Drive Next Cabinet Super Cycle
Narrative Update on Omnicell Analysts now see a slightly lower blended price target for Omnicell, with recent moves spanning a $14 cut at one firm and a $10 increase at another. They are weighing a new product cycle against differing views on execution and risk.Anlatı Güncellemesi • Apr 01
OMCL: Cabinet Replacement Cycle Will Drive Future Super Cycle Repricing
Narrative Update on Omnicell The updated analyst price target for Omnicell has shifted by $14 as analysts balance recent upgrades tied to a new product cycle and cabinet replacement opportunity against a lower target from one firm, while keeping the model's fair value estimate steady at $49. Analyst Commentary Recent research on Omnicell presents a mixed picture, with some firms highlighting upside linked to a new product cycle and cabinet replacement opportunity, while more cautious voices are resetting expectations and price targets.Anlatı Güncellemesi • Mar 18
OMCL: Cabinet Replacement Cycle Will Drive Future Risk Reward Repricing
Analysts have trimmed the Omnicell fair value estimate from $50.00 to $49.00, reflecting slightly softer assumptions for revenue growth and profit margins, even as they factor in a higher future P/E multiple supported by recent upgrades tied to the new product cycle and cabinet refresh story. Analyst Commentary Recent Street research on Omnicell has been mixed, with some firms trimming price targets while others turn more constructive on the new product cycle and cabinet refresh opportunity.Anlatı Güncellemesi • Mar 04
OMCL: Cabinet Replacement Cycle Will Drive Future Medication Management Upside
Analysts have adjusted their Omnicell price target by $14, reflecting mixed research that includes both target cuts and upgrades related to expectations around the new product cycle and potential cabinet replacement demand. Analyst Commentary Bullish Takeaways Bullish analysts see the new Titan XT cabinets as a key product that could support higher long term growth expectations if hospitals move ahead with planned cabinet replacements.Anlatı Güncellemesi • Feb 18
OMCL: Cabinet Refresh Cycle Will Support Future Medication Management Upside
Analysts have nudged their fair value estimate for Omnicell higher from $51.50 to about $57.43, citing updated views on its product cycle and cabinet refresh opportunity as reflected in recent research. Analyst Commentary Recent research coverage on Omnicell reflects a mix of optimism around the new product cycle and cabinet refresh, alongside some restraint on how quickly that opportunity may translate into value.Analiz Makalesi • Feb 12
Why Investors Shouldn't Be Surprised By Omnicell, Inc.'s (NASDAQ:OMCL) 26% Share Price Plunge
The Omnicell, Inc. ( NASDAQ:OMCL ) share price has softened a substantial 26% over the previous 30 days, handing back...Anlatı Güncellemesi • Feb 04
OMCL: Cabinet Replacement Cycle Could Drive Upside In Concentrated Market
Analysts have raised their fair value estimate for Omnicell to US$63 from US$55, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. This change is supported by recent positive research on the potential impact of the Titan XT cabinet cycle and competitive wins.Anlatı Güncellemesi • Jan 21
OMCL: Cabinet Replacement Cycle Will Shape Future Risk Reward Balance
Narrative Update on Omnicell The analyst price target for Omnicell has moved from $43 to $50 as analysts point to potential cabinet replacement demand and the Titan XT launch as key drivers for expected improvements in sales, earnings, and valuation assumptions. Analyst Commentary Recent research highlights a more constructive tone around Omnicell, with some analysts pointing to a potential cabinet replacement cycle and the Titan XT launch as key themes in their work.Anlatı Güncellemesi • Jan 06
OMCL: Future Medication Management Platform Rollout Will Support Balanced Risk Reward Profile
Analysts have lifted their price target on Omnicell from US$34 to US$43, pointing to updated assumptions for slightly lower discount rates, firmer revenue growth, improved profit margins, and a more moderate future P/E outlook. What's in the News Omnicell launched Omnicell Titan XT, an enterprise version of its automated dispensing systems designed to unify automation with its cloud-based OmniSphere medication management platform, aiming to create a connected, enterprise-wide medication management ecosystem across care areas.Anlatı Güncellemesi • Dec 18
OMCL: New Medication Management Platform Will Support Future Upside Potential
Analysts have raised their price target on Omnicell from approximately 47.33 dollars to 51.50 dollars. This change reflects slightly lower perceived risk, modestly stronger long term profit margins, and a higher expected future earnings multiple.Anlatı Güncellemesi • Dec 04
OMCL: Share Repurchases Will Support Future Upside Potential
Analysts have modestly raised their price target on Omnicell to approximately $47.33 per share, reflecting slightly lower perceived risk and stable, long-term growth and profitability expectations. What's in the News Updated fourth quarter 2025 revenue guidance to a range of $306 million to $316 million, signaling stable near term demand (company guidance).Anlatı Güncellemesi • Nov 20
OMCL: Share Repurchases And Executive Shifts Will Drive Future Upside
Analysts have revised their price target for Omnicell, lowering it modestly to $47.33 per share. This change reflects slight adjustments in key financial assumptions and uncertainty regarding future growth rates.Analiz Makalesi • Nov 13
Improved Revenues Required Before Omnicell, Inc. (NASDAQ:OMCL) Stock's 25% Jump Looks Justified
Omnicell, Inc. ( NASDAQ:OMCL ) shareholders would be excited to see that the share price has had a great month, posting...Anlatı Güncellemesi • Nov 06
OMCL: Share Repurchases And Leadership Transition Will Strengthen Market Position
Omnicell's analyst price target has been raised from $44 to approximately $47.33 per share. Analysts cite improved outlooks for revenue growth, profit margins, and lower discount rates as reasons supporting the upward revision.Seeking Alpha • Jul 31
Omnicell Q2 Earnings: Market Ignoring The Segments
Summary Omnicell's service business is rapidly growing, now 22% of revenue, outpacing industry trends and supporting long-term upside. My updated DCF analysis yields a price target of $57.46, representing 93% upside, with Wall Street consensus trailing behind. The primary risk is the pace of transition from product to service revenue, but a strong backlog mitigates margin and cash flow concerns. Given robust service growth and healthy backlog, I maintain Omnicell at strong buy, seeing current volatility as a long-term buying opportunity. Read the full article on Seeking AlphaAnaliz Makalesi • Jul 16
Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Analiz Makalesi • Jun 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Omnicell fair value estimate is US$40.16 Omnicell is estimated...Yeni Anlatı • May 27
Near-shoring And Digitization Will Drive Stability Despite Tariff Challenges
Supply chain improvements and near-shoring are expected to offset cost pressures, while a shift to recurring SaaS and services enhances earnings stability and valuation potential.Analiz Makalesi • May 14
It Looks Like Omnicell, Inc.'s (NASDAQ:OMCL) CEO May Expect Their Salary To Be Put Under The Microscope
Key Insights Omnicell's Annual General Meeting to take place on 21st of May CEO Randy Lipps' total compensation...Analiz Makalesi • May 09
US$38.50: That's What Analysts Think Omnicell, Inc. (NASDAQ:OMCL) Is Worth After Its Latest Results
There's been a notable change in appetite for Omnicell, Inc. ( NASDAQ:OMCL ) shares in the week since its first-quarter...Analiz Makalesi • Apr 07
Omnicell (NASDAQ:OMCL) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Mar 20
Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?
Omnicell, Inc. ( NASDAQ:OMCL ), is not the largest company out there, but it received a lot of attention from a...Analiz Makalesi • Feb 14
Why Omnicell's (NASDAQ:OMCL) Earnings Are Better Than They Seem
Despite posting healthy earnings, Omnicell, Inc.'s ( NASDAQ:OMCL ) stock has been quite weak. Our analysis suggests...Seeking Alpha • Feb 12
Omnicell Q4 Earnings: Ignore The Short-Term Noise
Summary Omnicell's Q4 2024 earnings showed strong service revenue growth, despite soft overall revenue guidance, highlighting the service business as the key value driver. My updated DCF analysis yields a price target of $64.05, representing a 54% upside, and I raise my rating from buy to strong buy. The service business has grown from 6% to 22% of revenue since 2020, outpacing industry growth and improving margins, indicating long-term value. Downside risks include the need to balance service growth with product decline, but the healthy backlog mitigates these concerns, presenting a buying opportunity. Read the full article on Seeking AlphaAnaliz Makalesi • Feb 09
Results: Omnicell, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
It's been a mediocre week for Omnicell, Inc. ( NASDAQ:OMCL ) shareholders, with the stock dropping 11% to US$40.16 in...Analiz Makalesi • Jan 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate
Key Insights Omnicell's estimated fair value is US$59.79 based on 2 Stage Free Cash Flow to Equity Omnicell's US$44.35...Hissedar Getirileri
| OMCL | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | 5.9% | -1.5% | 0.6% |
| 1Y | 53.1% | -19.9% | 19.5% |
Getiri vs. Endüstri: OMCL geçen yıl % -19.9 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: OMCL geçen yıl % 19.5 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| OMCL volatility | |
|---|---|
| OMCL Average Weekly Movement | 8.0% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: OMCL son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: OMCL 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1992 | 3,525 | Randy Lipps | www.omnicell.com |
Omnicell, Inc. iştirakleriyle birlikte Amerika Birleşik Devletleri'nde ve uluslararası alanda sağlık teknolojisi sağlamaktadır. Sağlık sisteminin hasta bakım alanlarındaki klinisyen iş akışları için bakım noktaları; otomatik bir dağıtım sistemi olan Titan XT; XT dolapları için bir konsol değişimi olan XTExtend ve ilaç dağıtım süreci için Merkezi Eczane Dağıtım Hizmeti gibi hastane ve sağlık sistemleri çözümleri sunmaktadır. Şirket ayrıca ilaç dağıtımı için Merkezi Med Otomasyon Hizmeti; kurum içi bir bileşik sistemi olan IV Bileşik Hizmeti; sağlık sistemlerinin kuruma ait bir özel eczane kurmasına, yönetmesine ve optimize etmesine yardımcı olacak anahtar teslim çözüm de dahil olmak üzere özel eczane hizmetleri; perakende ve toplum eczanelerini dijital olarak etkinleştirmek için EnlivenHealth platformu; sarf malzemeleri ve ilaç paketleme sistemlerinden oluşan ilaç bağlılık çözümleri; ve teknoloji uygulaması, müşteri eğitimi ve öğretimi, program yönetimi ve profesyonel hizmetlerle ilgili teklifler sunmaktadır.
Omnicell, Inc. Temel Bilgiler Özeti
| OMCL temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$2.05b |
| Kazançlar(TTM) | US$20.43m |
| Gelir(TTM) | US$1.23b |
101.5x
F/K Oranı1.7x
P/S OranıOMCL aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| OMCL gelir tablosu (TTM) | |
|---|---|
| Gelir | US$1.23b |
| Gelir Maliyeti | US$687.59m |
| Brüt Kâr | US$537.47m |
| Diğer Giderler | US$517.04m |
| Kazançlar | US$20.43m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 0.45 |
| Brüt Marj | 43.87% |
| Net Kâr Marjı | 1.67% |
| Borç/Özkaynak Oranı | 13.4% |
OMCL uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/09 04:00 |
| Gün Sonu Hisse Fiyatı | 2026/07/09 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Omnicell, Inc. 19 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Raymond Myers | Benchmark Company |
| William Sutherland | Benchmark Company |
| Zhilin Long | Berenberg |